The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis
Open accessAbstract
Amyotrophic lateral sclerosis ( ALS ) is the most common fatal motor neuron disease in adults. Numerous studies indicate that ALS is a systemic disease that affects whole body physiology and metabolic homeostasis. Using a mouse model of the disease ( SOD 1 G86R ), we investigated muscle physiology and motor behavior with respect to muscle metabolic capacity. We found that at 65 days of age, an age described as asymptomatic, SOD 1 G86R mice presented with improved endurance capacity associated with an early inhibition in the capacity for glycolytic muscle to use glucose as a source of energy and a switch in fuel preference toward lipids. Indeed, in glycolytic muscles we showed progressive induction of pyruvate dehydrogenase kinase 4 expression. Phosphofructokinase 1 was inhibited, and the expression of lipid handling molecules was increased. This mechanism represents a chronic pathologic alteration in muscle metabolism that is exacerbated with disease progression. Further, inhibition of pyruvate dehydrogenase kinase 4 activity with dichloroacetate delayed symptom onset while improving mitochondrial dysfunction and ameliorating muscle denervation. In this study, we provide the first molecular basis for the particular sensitivity of glycolytic muscles to ALS pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres
Lin, J., Wu, H., Tarr, P. T., Zhang, C.-Y., Wu, Z., Boss, O., Michael, L. F., Puigserver, P., Isotani, E., Olson, E. N., et al. (2002) · Nature · doi:10.1038/nature00904 · Cited by 2,546 · cited 1×
“…capacity and lipid use in muscle is accompanied by a switch in muscle fiber subtype, a phenomenon that is facilitated by peroxisome proliferatoractivated receptor gamma co-activator 1-alpha (PGC-1a), the master regulator of mitochondrial biogenesis and function (Wu et al, 1999; Lin et al, 2002).”
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis
Yamanaka, K., Chun, S. J., Boillee, S., Fujimori-Tonou, N., Yamashita, H., Gutmann, D. H., Takahashi, R., Misawa, H., & Cleveland, D. W. (2008) · Nature Neuroscience · doi:10.1038/nn2047 · Cited by 1,140 · cited 2×
“In recent years, several non-neuronal cells including microglia (Boillée et al, 2006), astrocytes (Yamanaka et al, 2008), and skeletal muscle (Wong & Martin, 2010) have been proposed to influence the course of the disease.”
Regulation of Muscle Fiber Type and Running Endurance by PPARδ
Wang, Y.-X., Zhang, C.-L., Yu, R. T., Cho, H. K., Nelson, M. C., Bayuga-Ocampo, C. R., Ham, J., Kang, H., & Evans, R. M. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020294 · Cited by 1,089
Bonnard, C., Durand, A., Peyrol, S., Chanseaume, E., Chauvin, M.-A., Morio, B., Vidal, H., & Rieusset, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32601 · Cited by 819
Clinical genetics of amyotrophic lateral sclerosis: what do we really know?
Andersen, P. M., & Al-Chalabi, A. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.150 · Cited by 687
McGarry, J. D., Mills, S. E., Long, C. S., & Foster, D. W. (1983) · Biochemical Journal · doi:10.1042/bj2140021 · Cited by 556 · cited 2×
“…the conversion of FA to AcylCoA (ACSF2), and the rate-limiting enzyme for b-oxidation responsible for the FA transfer into the mitochondria (CPT-1B) (McGarry et al, 1983) in asymptomatic SOD1G86R mice suggests that fatty acids intake is increased into glycolytic muscle tissue when ALS occurs.”
Peroxisome proliferator‐activated receptor δ controls muscle development and oxydative capability
Luquet, S., Lopez‐Soriano, J., Holst, D., Fredenrich, A., Melki, J., Rassoulzadegan, M., & Grimaldi, P. A. (2003) · The FASEB Journal · doi:10.1096/fj.03-0269fje · Cited by 509
Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation
Holness, M. J., & Sugden, M. C. (2003) · Biochemical Society Transactions · doi:10.1042/bst0311143 · Cited by 479
Mitochondrial and cellular mechanisms for managing lipid excess
Aon, M. A., Bhatt, N., & Cortassa, S. C. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00282 · Cited by 253 · cited 1×
“Increased b-oxidation of fatty acids leads to the generation of lipid by-products that contribute to lipotoxicity and ROS production (Zhang et al, 2010; Aon et al, 2014).”
Cited by
Neuronal Lipid Metabolism: Multiple Pathways Driving Functional Outcomes in Health and Disease
Tracey, T. J., Steyn, F. J., Wolvetang, E. J., & Ngo, S. T. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00010 · Cited by 433
Self-citationEnergy metabolism in ALS: an underappreciated opportunity?
Vandoorne, T., De Bock, K., & Van Den Bosch, L. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1835-x · Cited by 262
Linking mitochondrial dysfunction, metabolic syndrome and stress signaling in Neurodegeneration
Jha, S. K., Jha, N. K., Kumar, D., Ambasta, R. K., & Kumar, P. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.06.015 · Cited by 122
Peter, R. S., Rosenbohm, A., Dupuis, L., Brehme, T., Kassubek, J., Rothenbacher, D., Nagel, G., & Ludolph, A. C. (2017) · European Journal of Epidemiology · doi:10.1007/s10654-017-0318-z · Cited by 113
Physiological changes in neurodegeneration—mechanistic insights and clinical utility
Ahmed, R. M., Ke, Y. D., Vucic, S., Ittner, L. M., Seeley, W., Hodges, J. R., Piguet, O., Halliday, G., & Kiernan, M. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.23 · Cited by 91
PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia
Pin, F., Novinger, L. J., Huot, J. R., Harris, R. A., Couch, M. E., O'Connell, T. M., & Bonetto, A. (2019) · The FASEB Journal · doi:10.1096/fj.201802799r · Cited by 81
Burg, T., Rossaert, E., Moisse, M., Van Damme, P., & Van Den Bosch, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011224 · Cited by 50
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Jawaid, A., Khan, R., Polymenidou, M., & Schulz, P. E. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0294-0 · Cited by 37
Abnormal energy metabolism in ALS: a key player?
Burg, T., & Van Den Bosch, L. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001164 · Cited by 24
Metadata
- Authors
- Palamiuc, L., Schlagowski, A., Ngo, S. T., Vernay, A., Dirrig‐Grosch, S., Henriques, A., Boutillier, A., Zoll, J., Echaniz‐Laguna, A., Loeffler, J., & René, F.
- Venue
- EMBO Molecular Medicine
- Published
- 2015-03-27
- Volume
- 7
- Issue
- 5
- Pages
- 526-546
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W1991567522
- Cited by
- 233
- References
- 14
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.